Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson’s Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway | Zendy

Wei Xu | Zendy; Deyu Zheng | Zendy; Yuanyuan Liu | Zendy; Ji Li | Zendy; Yang Li | Zendy; Xiuli Shang | Zendy

Open Access

Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson’s Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway

Author(s) -

Wei Xu,

Deyu Zheng,

Yuanyuan Liu,

Ji Li,

Yang Li,

Xiuli Shang

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000485947

Subject(s) - oxidative stress , inflammation , chemistry , neurotoxicity , pharmacology , substantia nigra , nf κb , dopaminergic , immunology , biology , endocrinology , biochemistry , dopamine , toxicity , organic chemistry

Parkinson's disease (PD) is a common neurodegenerative disease in the old population, characterized by dopaminergic neuron loss, inflammation and oxidative stress injury in the substantia nigra. Glaucocalyxin B (GLB), an ent-kauranoid diterpenoid isolated from Rabdosia japonica, has anti-inflammation and anti-tumor effects. However, its effects on PD remain unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research